Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Roche’s Home Healthcare Medical Device For Anticoagulant Therapy Launches In Europe

XTALKS VITALS NEWS

The Switzerland-based company’s medical device – CoaguChek INRange – monitors a patient’s response to Vitamin K Antagonist (VKA) therapy by measuring blood coagulation.

Share this!

June 2, 2016 | by Sarah Massey, M.Sc.

Roche has launched a new PT/INR home self-testing device for European patients taking anticoagulant drugs Tweet: Roche launches home #medicaldevice for patients taking anticoagulants http://ctt.ec/xovq6+. The home healthcare medical device market is a growing space, and new products have the potential to improve out-of-hospital care for patients.

The Switzerland-based company’s medical device – CoaguChek INRange – monitors a patient’s response to Vitamin K Antagonist (VKA) therapy by measuring blood coagulation. Since the medical device makes use of Bluetooth technology, it could help patients and physicians monitor treatment success more effectively compared to the current standard of care.

Currently, patients must visit a hospital or doctor’s office in order to assess how well they are responding to VKA therapy. The PT/INR testing is done using a blood test, for which lab results could take two to three days to be generated.

Roche’s CoaguChek INRange medical device uses a fingerstick – much like a glucose meter – with results in just 60 seconds. Along with reducing the number of visits to a physician’s office, the medical device could improve patient adherence to a monitoring schedule, thereby improving patient outcomes.



“In a clinical environment, we need to establish a model of care that empowers patients, helping them to understand their health condition and allowing them to take responsibility of their own health care needs,” said Dr. Juan Carlos Souto, of the Hospital de Sant Pau in Barcelona, Spain. “The new technology will enable us to access the test results in the clinic's database, to keep track of the individual patient's status and to measure the quality of care provided by our clinic.”

According to Roche, research has shown that patients using self-testing monitoring devices spend more time at normal INR levels, and may have a lower risk of bleeding and stroke. The company’s home testing medical device could also strengthen the doctor-patient relationship by facilitating communication.

“As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important,” said Roland Diggelmann, COO of Roche Diagnostics. “This is another proof point towards our aim to position patient self-testing as the standard of care to monitor VKA therapy.”


Keywords: Medical Device, Anticoagulant, Home Healthcare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.